Bronchodilator reversibility in patients with asthma and persistent airflow limitation

Ernesto Crisafulli¹, Giulia Sartori², Vincenzo Patruno³, Alberto Fantin³

Affiliations

¹ Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, 37124, Italy. Electronic address: ernesto.crisafulli@univr.it.
² Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, 37124, Italy.
³ Department of Pulmonology, S. Maria della Misericordia University Hospital, Udine, Italy.

PMID: 36332640
DOI: 10.1016/S2213-2600(22)00363-0

Comment

Bronchodilator reversibility in patients with asthma and persistent airflow limitation

Ernesto Crisafulli et al. Lancet Respir Med. 2022 Nov.

. 2022 Nov;10(11):e94-e95.

doi: 10.1016/S2213-2600(22)00363-0.

Authors

Ernesto Crisafulli¹, Giulia Sartori², Vincenzo Patruno³, Alberto Fantin³

Affiliations

¹ Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, 37124, Italy. Electronic address: ernesto.crisafulli@univr.it.
² Department of Medicine, Respiratory Medicine Unit, University of Verona and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, 37124, Italy.
³ Department of Pulmonology, S. Maria della Misericordia University Hospital, Udine, Italy.

PMID: 36332640
DOI: 10.1016/S2213-2600(22)00363-0

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. We thank Sabrina Peroni, Mariagrazia Morcone and Nicolò Ridella for their support in collecting data.

Comment in

Bronchodilator reversibility in patients with asthma and persistent airflow limitation - Authors' reply.
Kole TM, Kerstjens HAM, van den Berge M; ATLANTIS, UBIOPRED, CADSET contributors. Kole TM, et al. Lancet Respir Med. 2022 Nov;10(11):e96. doi: 10.1016/S2213-2600(22)00366-6. Lancet Respir Med. 2022. PMID: 36332641 No abstract available.

Comment on

Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study.
Kole TM, Vanden Berghe E, Kraft M, Vonk JM, Nawijn MC, Siddiqui S, Sun K, Fabbri LM, Rabe KF, Chung KF, Nicolini G, Papi A, Brightling C, Singh D, van der Molen T, Dahlén SE, Agusti A, Faner R, Wedzicha JA, Donaldson GC, Adcock IM, Lahousse L, Kerstjens HAM, van den Berge M; ATLANTIS; U-BIOPRED; CADSET investigators. Kole TM, et al. Lancet Respir Med. 2023 Jan;11(1):55-64. doi: 10.1016/S2213-2600(22)00185-0. Epub 2022 Jul 27. Lancet Respir Med. 2023. PMID: 35907424

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Bronchodilator reversibility in patients with asthma and persistent airflow limitation

Affiliations

Bronchodilator reversibility in patients with asthma and persistent airflow limitation

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical